Title	Published	Price
MarketVIEW: Lyme borreliosis vaccines (CAT No: VAMV024) By: VacZine Analytics ... is large areas of Europe and North America, can cause a wide range of disease symptoms which range from a mild treatable rash to serious complications of the neurological system (neuroborreliosis). The incidence of LB ... \| more...	10/1/2010	$7,995.00
MarketVIEW: Norovirus vaccines (CAT No: VAMV015) By: VacZine Analytics ... symptoms usually resolving after 1 to 3 days. However, it is the sheer volume of infections and burden on healthcare systems that presents the biggest challenge. In the US, NV infections may account for 235,000 ... \| more...	7/1/2010	$7,995.00
MarketVIEW: Cytomegalovirus Vaccines By: VacZine Analytics ... other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system ... \| more...	6/1/2010	$7,995.00
MarketVIEW: Pseudomonas aeruginosa vaccines (CAT No: VAMV010) By: VacZine Analytics ... variety of patient groups but mainly those with lung dysfunction such as pneumonia (ICU), COPD and Cystic fibrosis. Other important risk groups are severe burns patients. Although PA infections are treatable, many forms of PA ... \| more...	5/1/2010	$7,995.00
MarketVIEW: Staphylococcus aureus vaccines (CAT No: VAMV002) By: VacZine Analytics ... expensive infection control interventions e.g. MRSA screening on admission. Although all major companies have now announced S.aureus vaccine programs, Merck & Co (Intercell AG) are the most advanced (Phase II/III). If successful Merck & Co ... \| more...	4/1/2010	$7,995.00
MarketVIEW: Meningitis ACWY vaccines By: VacZine Analytics ... where 5 main serogroups ACWY and B are responsible for the majority of disease. Conjugated vaccines to prevent meningococcal disease have had successful impact especially in the United Kingdom (serogroup C, implemented 1999). In 2005, ... \| more...	3/1/2010	$7,995.00
DiseaseINFOPACK: Clostridium difficile in China By: VacZine Analytics ... C.diff epidemiology is accumulating in Western markets, a lot less is known in large emerging nations such as China. Information is required to understand whether the extent of disease epidemiology and associated dynamics is similar ... \| more... Search inside this report	11/1/2009	$4,895.00
DiseaseINFOPACK: Streptococcus dysgalactiae By: VacZine Analytics ... Streptococcus (GAS) (1). These diseases include superficial skin infections, pharyngitis and life threatening conditions such as Streptococcal toxic shock syndrome (STSS). SDSE may express group A, group C or group G Lancefield antigens, but generally ... \| more... Search inside this report	9/1/2009	$4,895.00
MarketVIEW: H1N1 vaccine (Global demand model) By: VacZine Analytics ... confirmed cases and 4500 reported deaths globally due to the virus. Vaccine manufacturers are now actively producing H1N1 pandemic specific vaccines which are now reaching regulatory approval in the US and EU. The US ACIP ... \| more...	9/1/2009	$5,995.00
MarketVIEW: Group B Streptococcus vaccines By: VacZine Analytics ... threatening sepsis and meningitis (early and late onset disease) due to ascending spread of GBS from the birth canal of colonized females (~30% of total) who are typically asymptomatic. In the 1970s GBS was the ... \| more...	9/1/2009	$6,995.00
DiseaseINFOPACK: Enterovirus-71 By: VacZine Analytics ... significance, EV-71 appears an attractive target for a vaccine-based preventative approach. This expert DiseaseINFOPACK report gives a comprehensive situation overview of current EV-71 disease dynamics and regional epidemiology. EV-71 is under consideration by a number ... \| more... Search inside this report	8/1/2009	$4,895.00
MarketVIEW: Chikungunya virus By: VacZine Analytics ... many organizations, including biotechs and the US/French military have considered the prospect for a prophylatic vaccine which could be used in stationed troops, travellers and vulnerable residents of endemic areas. This expert report comprises of ... \| more...	6/1/2009	$7,995.00
DiseaseINFOPACK: Chikungunya virus By: VacZine Analytics ... disease (encephalopathy). Although CHIK is endemic in Africa/Southeast Asia, recent outbreaks during 2004-2007 have reached new geographical areas where cases are now reported in Europe, Hong-Kong, Canada, Taiwan and the USA. In some cases, these ... \| more...	5/1/2009	$4,895.00
MarketVIEW: H1N1 vaccine (US demand model) By: VacZine Analytics ... infection with over half of the cases being identified in the continental United States. Using currently available information regarding the expected profile, possible allocation of H1N1 specific vaccine and predictions of pandemic severity, VacZine Analytics ... \| more...	5/1/2009	$1,995.00
MarketVIEW: pre-pandemic vaccines By: VacZine Analytics ... has caused high mortality in poultry and occasionally infects humans in close contact with around 60% of cases (408) so far being fatal. As of February 27th 2009 confirmed H5N1 Avian influenza deaths in humans ... \| more... Search inside this report	3/1/2009	$8,995.00
Diseaseinfopack: Pre-pandemic Vaccines By: VacZine Analytics ... H5N1 Avian influenza deaths in humans have reached 256, a significant increase upon 2004 when measurements began. This expert report provides a comprehensive up-to-date critical review of current global pandemic preparedness and planning with regard ... \| more... Search inside this report	3/1/2009	$6,995.00
DiseaseINFOPACK: Non-typeable Haemophilus influenzae By: VacZine Analytics ... and adults. In the US, the Centers For Disease Control (CDC) and Prevention estimates that H.influenzae caused greater than 4,500 cases of invasive disease resulting in 405 deaths in 2007 of which around 60% of ... \| more... Search inside this report	3/1/2009	$4,895.00
Vaccine Pipeline Review - Oct 2008 By: VacZine Analytics ... companies. It can be used for competitive intelligence, business development and strategic planning activities. In the database, each program comes with predicted BLA and MAA filing dates along with key details such as clinical trial ... \| more...	10/1/2008	$8,995.00
MarketVIEW: Chlamydia trachomatis vaccines By: VacZine Analytics ... reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are “silent” and unrecognized. ... \| more...	10/1/2008	$8,995.00
Disease INFOPACK: Norovirus By: VacZine Analytics ... the elderly in long-term care facilities and hospitals. Although Noroviruses cause a mild illness of short duration, severe dehydration or electrolyte imbalance can be a contributing cause to death in vulnerable populations. Significantly, current evidence ... \| more...	9/1/2008	$4,595.00
OpportunitySCAN: Staphylococcus aureus vaccines By: VacZine Analytics ... and EU regarding current disease dynamics and the scientific viability of immunologic based strategies. Within the document, the reader can access target product profiles (TPPs) for the vaccine, along with definition of target populations and ... \| more...	9/1/2008	$8,995.00
MarketVIEW: Clostridium difficile Vaccines By: VacZine Analytics ... forecasting the potential commercial value of a prophylactic C.diff vaccine across the seven major markets. The model contains value ($ m) and volume (mio doses) estimates in both community and hospitalized populations along with predictions ... \| more...	8/1/2008	$8,995.00
OpportunitySCAN: Clostridium difficile vaccines By: VacZine Analytics ... regarding current disease dynamics and the scientific viability of immunologic based strategies. Within the document, the reader can access target product profiles (TPPs) for the vaccine in the pre-exposure and therapeutic settings, along definition of ... \| more...	8/1/2008	$8,995.00
Disease INFOPACK: Group A Strep (invasive) By: VacZine Analytics ... infections range from mild superficial infections such as pharyngitis “strep throat” to severe invasive life-threatening diseases such as necrotizing fasciitis (NF) or “flesh eating disease”. GAS is also responsible for rheumatic heart disease which is ... \| more... Search inside this report	7/1/2008	$4,595.00
Disease INFOPACK: Respiratory Syncytial Virus (elderly) By: VacZine Analytics ... RSV is a common pathogen in infants it also causes significant disease burden in adults with a compromised immune or respiratory system such as the elderly or those with chronic obstructive pulmonary disease (COPD). This ... \| more... Search inside this report	6/1/2008	$4,595.00
Title	Published	Price

< prev 1 2 next >

Title Index: # | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

MarketResearch.com

Our People

On The Web

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: Monday - Thursday: 5:30am - 7:00pm EST

Fridays: 5:30am - 6:00pm EST